Memory Study of Youngest Women Enrolled in the Women's Health Initiative Hormone Therapy (HT) Arm
This trial is active, not recruiting.
|Sponsor||Wake Forest Baptist Health|
|Start date||June 2009|
|End date||May 2016|
|Trial size||1362 participants|
|Trial identifier||NCT01124773, 699|
WHIMS-Y will provide the WHI information on one of the most enduring negative consequences of postmenopausal HT; a relative deficit in cognitive function and an increased risk for clinically significant cognitive impairment that remain in the cohort after the cessation of study-prescribed HT.
Women who were aged 50-54 at the time of randomization into the WHI hormone trials.
time frame: Measured once a year
Mild Cognitive Impairment
time frame: 1 time per year
Female participants from 50 years up to 54 years old.
Inclusion Criteria: - Must be enrolled in the Women's Health Initiative Extension Exclusion Criteria: - Not enrolled in the Women's Health Initiative Extension
|Official title||Women's Health Initiative Memory Study of Younger Women|
|Principal investigator||Stephen R Rapp, PhD|
|Description||The Women's Health Initiative Memory Study of Younger Women (WHIMS-Y) is proposed to assess the long-term impact of random assignment to postmenopausal hormone therapy (Medroxyprogesterone, Estrogens, Conjugated or Estrogen-only or placebo) among women who were aged 50-54 at the time of randomization into the WHI hormone trials. Secondary objectives relate to the consistency of any treatment effects across unopposed or opposed therapy and whether there exists evidence of graded relationships between cognitive effects and age of administration, years from menopause, and baseline risk factors for cognitive impairment.|
Call for more information